All Title Author
Keywords Abstract


Investigation Correlates of Chlamydia Anti-Body Testing and Hysterosalpingography among Women with Tubal Infertility

DOI: 10.4236/ojog.2014.416148, PP. 1077-1081

Keywords: Sero-Prevalence, Chlamydia trachomatis, IgG Antibodies, IgM Antibodies, Tubal Infertility

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Chlamydia trachomatis infection is an important preventable cause of infertility. In women, up to 70% of genital infection with Chlamydia trachomatis are asymptomatic. In the management of infertility patients, a lot of clinicians or centres do not routinely screen for Chlamydia trachomatis infection. Hence all patients being investigated for infertility may potentially be at risk of tubal blockage in addition to non-tubal factor aetiology. Those with primary tubal blockage also are at risk of worsening of the blockage. Objective: To determine if there is a relationship between IgG and IgM Chlamydia antibody testing (CAT) and tubal factor infertility. Design: It was a cross sectional descriptive study. Method: The sera of 400 consecutive consenting infertile patients presenting to the gynaecological clinic of the Ahmadu Bello University Teaching Hospital, Zaria, Northern Nigeria were tested for Chlamydia antibodies using ELISA IgG and IgM kits produced by Diagnostic Automation, Inc., 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302, USA. Results: Up to 264 (66%) of the patients had tubal factor, 64 (16%) had uterine, 56 (14%) had ovarian, 50 (12.5%) had male while 40 (10%) had others. The causative factors were not mutually exclusive. The sero-prevalence of IgG and IgMChlamydia trachomatis

References

[1]  Posada, C., Jonasson, J., et al. (1992) Prevalence of Urogenital Chlamydia Trachomatis Infection in EL-Salvador— Infection during Pregnancy and Perinatal Transmission. International Journal of STD & AIDS, 3, 33-37.
[2]  Moussavi, Z. and Behrouzi, R. (1996) The Prevalence of Chlamydia Infection among Pregnant Women Referred to Perinatal Clinics of Tehran University of Medical Sciences in IRAN. 25th Congress of Medical Women’s International Association. http://www.regional.org.au/au/mwia/papers/full/20_moussavi.htm
[3]  Centre for Disease Control and Prevention (2006) Guidelines for Treatment of Sexually Transmitted Diseases. Morbid/Mortal Weekly Report, 55, 11. http://www.cdc.gov/std/treatment/2006/rr5511.pdf
[4]  Isibor, J.O., Ugbomoiko, D., et al. (2005) Detection of Chlamydia Antigen in Cervical Specimens from Antenatal Clinic Attendees in Benin City, Nigeria. African Journal of Clinical and Experimental Microbiology, 6, 208-211.
[5]  Haggerty, C.L., Gottlieb, S.L., Taylor, B.D., Low, N., Xu, F. and Ness, R.B. (2010) Risk of Sequelae after Chlamydia Trachomatis Genital Infection in Women. The Journal of Infectious Diseases, 201, S134-S155.
[6]  Tukur, J., Shittu, S.O. and Abdul, A.M. (2006) A Case Control Study of Active Genital Chlamydia trachomatis Infection among Patients with Tubal Infertility in Northern Nigeria. Tropical Doctor, 36, 14-16. http://www.ncbi.nlm.nih.gov/pubmed/16483420
[7]  Rastogi, S., Kapur, S., et al. (1999) Chlamydia Trachomatis Infection in Pregnancy Risk Factor for an Adverse Outcome. British Journal of Biomedical Science, 56, 94-98.
[8]  Omo-Aghoja, L.O., Okonofua, F.E., Larsen, U. and Bergstrom, S. (2007) Association of Chlamydia trachomatis Serology with Infertility in Nigerian Women. Journal of Obstetrics and Gynaecology Research, 33, 688-695.
[9]  Cooke, I.D. (2007) The Globalization of Reproductive Technology. In: Kruger, T.F., van der Spuy, Z. and Kemper, B.D., Eds., Advances in Fertility Studies and Reproductive E Medicine, Cape Town Juticalpa, 234-240.

Full-Text

comments powered by Disqus